AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04432597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (Phase I)
Description: Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants).
Study NCT04432597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (Phase II)
Description: Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants).
Study NCT02526732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual training program
Description: Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
Study NCT00642512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol
Description: 10 - 20 mg
Study NCT00642512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: 8 - 16 mg
Study NCT00642512 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dronabinol/ondansetron
Description: 10 - 20 mg/8 - 16 mg
Study NCT00642512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03190473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES
Description: PCI with implantation of a DES
Study NCT03190473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES
Description: PCI with implantation of a DES
Study NCT03491644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titrated Oxygen
Description: Restrictive treatment with oxygen.
Study NCT03491644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Oxygen
Description: Liberal treatment with oxygen.
Study NCT02210364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) 1 mg and 4 mg vials
Study NCT02210364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 150 mg tablets
Study NCT01402453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentives
Description: Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
Study NCT01402453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrinsic Motivation
Description: A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
Study NCT03302338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAFE group
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
Study NCT03302338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: distilled water 20 ml/kg/day for maximum of 7 days.
Study NCT02449200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
Study NCT02265562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
Study NCT02265562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 minutes before the surgery 2 tablet of placebo inserted rectally
Study NCT03321331 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lark (JITAI)
Description: Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
Study NCT03321331 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MyFitnessPal (no JITAI)
Description: MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
Study NCT00881387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00881387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00881387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV
Study NCT04380402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40 mg tablet
Study NCT01380340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seniors Early Intervention Planning and Discussion.
Description: The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
Study NCT04907708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Euglycemic agent
Study NCT04907708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Hypoglycemic agent
Study NCT04001673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist's intervention
Description: Information about bDMARDs management.
Study NCT03724643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized wean
Description: Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2\< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
Study NCT04088552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go4Life-Physical Activity/Exercise Program Workout to Go 5
Description: The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen.
Study NCT04088552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActuaYa Educational Sessions
Description: The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
Study NCT02522494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: An educational intervention delivered prior to patients' visits with primary care physicians.
Study NCT02522494 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pamphlet
Description: An educational intervention delivered prior to patients' visits with primary care physicians.
Study NCT02522494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: An educational intervention delivered prior to patients' visits with primary care providers.
Study NCT02291887 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: Intravitreal injection of Ranibizumab
Study NCT02291887 — intervention group
Intervention type: DRUG
Intervention: Aflibercept
Description: Intravitreal injection of Aflibercept
Study NCT01443481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
Study NCT00328510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTC frame
Study NCT00328510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic facemask
Study NCT00328510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy
Study NCT01988311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol
Study NCT03750474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: magnetic resonance elastography and shear wave elastography
Description: magnetic resonance elastography and shear wave elastography of the back muscles
Study NCT03750474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance elastography and shear wave elastography
Description: magnetic resonance elastography and shear wave elastography of the back muscles
Study NCT01427920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
Study NCT01427920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
Study NCT03235167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG DNA
Description: CpG DNA concentrate
Study NCT03235167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter arterial chemoembolization
Description: transcatheter arterial chemoembolization (TACE) therapy for liver cancer
Study NCT03235167 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transcatheter arterial chemoembolization
Description: transcatheter arterial chemoembolization (TACE) therapy for liver cancer
Study NCT03235167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: CpG DNA vehicle
Study NCT01717456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
Study NCT01717456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber supplements
Description: Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
Study NCT01717456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber supplements
Description: Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
Study NCT01717456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laxatives or anti-diarrheals
Description: Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed.
Study NCT01717456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
Study NCT01717456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tips on how to prevent fecal incontinence
Description: Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze.
Study NCT03315871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
Study NCT03315871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
Study NCT03315871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C (M7824)
Description: Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
Study NCT03315871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
Study NCT01717118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Vaccines
Study NCT01717118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetravalent Vaccine
Study NCT01605513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon
Description: PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
Study NCT04217863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDP
Description: Guided Disclosure Protocol
Study NCT04064034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Flow Assay (LFA)
Description: Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
Study NCT03663231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene
Description: Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
Study NCT03663231 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IND/IDE exempt device primarily water
Study NCT00725452 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
Study NCT03346226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
Study NCT03346226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
Study NCT04589624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT04589624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04589624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo hpMRI
Study NCT02210117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02210117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02210117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02210117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02210117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy
Study NCT02210117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02210117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo nephrectomy
Study NCT02593994 — intervention group
Intervention type: DEVICE
Intervention: Onyx Drug Eluting Stent group
Study NCT01352338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, endoxan, prednisone
Description: dose-finding
Study NCT02490059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Bronchoscopy for diagnosis of pulmonary nodules
Study NCT01352338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide, endoxan, prednisone
Description: oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03203369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART123
Description: Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
Study NCT02998281 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Threshold (IMT)
Description: Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
Study NCT02998281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold (IMT)
Description: Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
Study NCT02264028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [14C]-DK-AH 269 CL, solution for infusion
Study NCT02264028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DK-AH 269 CL, drinking solution
Study NCT03229954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside (Monofer) intravenous infusion
Description: The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety.